Quick Answer
Akebia Therapeutics, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $236.20 million for the year ending 2025.
- Akebia Therapeutics, Inc. showed an increase of +47.5% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Akebia Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), Akebia Therapeutics, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 15,287.4%.
- Historical annual values: Fiscal year 2025: $236.20 million | Fiscal year 2024: $160.18 million | Fiscal year 2023: $194.62 million | Fiscal year 2022: $292.48 million | Fiscal year 2021: $213.58 million | Fiscal year 2020: $295.31 million | Fiscal year 2019: $335.00 million | Fiscal year 2018: $207.74 million | Fiscal year 2017: $181.23 million | Fiscal year 2016: $1.54 million.
- Data sourced from SEC EDGAR public filings as of June 24, 2026.
Last verified: